Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Director · President & CEO | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 128,791 |
Reported balance
After 2026-08-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 60,200 · Balance 128,791 F1: The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date. F2: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date.
F2: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 20:23 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 60,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001760123-26-000004 · form4-08122026_080836.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,791 F1 · shares: The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date. F2 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:23 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 380,000 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001760123-26-000002 · form4-06032026_090640.xml · derivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,000 Underlying: Voting Common Shares · 380,000 shares Expires 2036-06-01 F1 · derivative.exercise_date: Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:18 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001437749-25-019294 · rdgdoc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Shares · 600,000 shares Expires 2035-05-31 F2 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:41 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000050 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:34 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 12,787 | $3.91 | $49,997.17 |
DisclosureSEC source: 0001235802-23-000072 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,591 F1 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:39 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock option (right to buy) · Derivative | 181,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000061 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,000 Underlying: Common Shares · 181,000 shares Expires 2033-05-31 F2 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 01:56 UTC | DiaMedica Therapeutics Inc. DMAX · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 20,000 | $1.21 | $24,200.00 |
DisclosureSEC source: 0001235802-22-000121 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.17 to $1.21, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:06 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 177,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001235802-22-000076 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Shares · 177,000 shares Expires 2032-05-31 F2 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2023 and with respect to the remaining 75% of the underlying common shares in 36 as nearly equal as possible monthly installments commencing on July 1, 2023. Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 20:19 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 5,000 | $3.14 | $15,700.00 |
DisclosureSEC source: 0001235802-21-000098 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.12 to $3.15, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 01:07 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000092 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Shares · 175,000 shares Expires 2031-07-27 F2 · derivative.exercise_date: Vests in sixteen nearly equal quarterly installments over four years. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:19 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000053 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Shares · 56,000 shares Expires 2030-05-31 F2 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments commencing on September 1, 2020. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 20:31 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 1,000 | $2.68 | $2,676.90 |
DisclosureSEC source: 0001235802-19-000105 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,804 F1 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:42 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 264,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000064 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,000 Underlying: Common Shares · 264,000 shares Expires 2029-06-23 F2 · derivative.exercise_date: Vests in eight equal quarterly installments over two years. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:31 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 5,000 | $4.00 | $20,000.00 |
DisclosureSEC source: 0001235802-18-000182 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,804 F1 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.